Invited to the “Choose France” summit in Versailles, the president of the GSK pharmaceutical laboratories announced an investment plan that will benefit the group’s three sites in France.
As part of the “Choose France” summit, the pharmaceutical companies GSK announce an investment of 400 million euros, and are currently recruiting on two of their three French sites, announced Monday, May 15 on franceinfo Thibault Desmarest, president of GSK France .
In detail, GSK has opened 100 positions on its Saint-Amand-les-Eaux site (North), where most of the group’s vaccines are produced, against shingles or malaria, for example. In Mayenne, where GSK produces antibiotics and in particular amoxicillin, “80 positions are open”, assures Thibault Desmarest. The group has a third site, in Evreux, where respiratory products are manufactured.
A three-year investment plan
These three sites will benefit greatly from the investment of 400 million euros announced by GSK over the next three years. “240 million euros will go to our industrial sites to modernize, digitize but also decarbonize”, ensures Thibault Desmarest, “and 150 million will go to research and development in France”.
On this last point, GSK also hopes to first release the vaccine against respiratory syncytial virus (RSV), the equivalent of bronchiolitis for the elderly: “We have been doing research on this vaccine for 60 years, it has just been approved in the United States, we hope that it will be approved this summer in Europe.” The RSV is responsible “20,000 deaths in Europe and 300,000 hospitalizations each year”, according to Thibault Desmarest. The president of GSK France hopes for rapid validation, perhaps by next winter, for “help unclog our hospitals”.